Tag

Novartis

All articles tagged with #novartis

business22 hours ago•2 min saved

Atrium Therapeutics spins out from Novartis-Avidity deal with two cardio RNA therapies

Atrium Therapeutics, a spinout formed from Novartis's $12 billion acquisition of Avidity Biosciences, debuts with $270 million in cash and two preclinical RNA interference assets (ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy). Led by Kathleen Gallagher, Atrium plans a Phase 1 trial for ATR 1072 in the second half of this year and for ATR 1086 in 2027, with the new ticker RNAM, inheriting Avidity's market position.

via Fierce Biotech|

#atrium-therapeutics #avidity-biosciences #business

health1 day ago•3 min saved

Lacks Family Reaches Confidential Pact With Novartis Over HeLa Cells

The family of Henrietta Lacks has reached a second confidential settlement with Novartis over profits from her immortal HeLa cells, continuing a long fight for compensation; terms are undisclosed and follow a prior settlement with Thermo Fisher, underscoring ongoing ethical questions about consent and the benefits derived from her cells.

via BBC|

#bioethics #health #hela

health3 days ago•14 min saved

Novartis settles with Lacks family over HeLa cell legacy

Novartis has reached a settlement with Henrietta Lacks' estate over the use of her HeLa cells in medical research, ending a dispute with undisclosed terms; the case highlights ongoing debates about consent and compensation tied to the iconic cell line used in biomedical advances since 1951.

via AP News|

#bioethics #health #hela

health1 month ago•8 min saved

Global push to end leprosy gains momentum ahead of World Leprosy Day

WHO renews its commitment to a leprosy-free world ahead of World Leprosy Day, highlighting free multidrug therapy and post-exposure prophylaxis, a 25-year partnership with novartis, and ongoing anti-stigma efforts, while noting 172,717 new cases in 2024 across 188 reporting areas.

via World Health Organization (WHO)|

#global-health-partnerships #health #leprosy

business1 month ago•3 min saved

Tariffs Tighten Markets as Dalio, Jassy, Narasimhan Speak

A Seeking Alpha roundup features Ray Dalio warning that Trump's aggressive foreign policy could deter foreign investors from U.S. assets, Amazon noting tariffs are lifting some prices and slowing inventory turnover, and Novartis stating its U.S. investments and trade deals should shield it from most tariffs with contingency plans in place.

via Seeking Alpha|

#amazon #business #markets

business4 months ago•0 min saved

Novartis's $12B Avidity Deal Boosts Biotech Stocks and Neuroscience Pipeline

Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.

via Endpoints News|

#acquisition #avidity-biosciences #biotech

business4 months ago•3 min saved

Novartis Nears $12 Billion Deal to Acquire Avidity Biosciences

Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.

via Reuters|

#acquisition #avidity-biosciences #biotech

business4 months ago•11 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Neuroscience Pipeline

Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.

via Novartis|

#acquisition #avidity-biosciences #business

business4 months ago•1 min saved

Novartis Approaches $12 Billion Acquisition of Avidity Biosciences

Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.

via Financial Times|

#acquisition #avidity-biosciences #business

business4 months ago•1 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion in Cash

Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.

via CNBC|

#acquisition #avidity-biosciences #biotech

business4 months ago•1 min saved

Novartis Nears $10 Billion Deal to Acquire Avidity Biosciences

Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.

via Bloomberg.com|

#avidity-biosciences #biotechnology #business

healthcare5 months ago•8 min saved

Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria

Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.

via Novartis|

#chronic-spontaneous-urticaria #fda-approval #healthcare

business5 months ago•0 min saved

Monte Rosa’s Stock Soars After $5.7B Novartis Deal

Monte Rosa's stock (GLUE) surged following a $5.7 billion deal with Novartis, significantly impacting its market value.

via TipRanks|

#business #deal #glue

business5 months ago•9 min saved

Novartis to Acquire Tourmaline Bio to Strengthen Cardiovascular Pipeline

Novartis plans to acquire Tourmaline Bio for approximately USD 1.4 billion, gaining access to the Phase 3 ready asset pacibekitug, an anti-IL-6 monoclonal antibody targeting systemic inflammation in atherosclerotic cardiovascular disease, which shows promising results in reducing inflammation markers and addresses an unmet need in cardiovascular risk reduction.

via Novartis|

#acquisition #anti-il-6 #business

healthcare6 months ago•8 min saved

Novartis achieves breakthrough in Sjögren’s syndrome with successful Phase III trials

Novartis announced positive results from its Phase III trials of ianalumab, demonstrating significant improvement in disease activity for Sjögren’s disease, potentially making it the first targeted treatment for this autoimmune disorder. The trials showed the drug was well tolerated and could soon be submitted for regulatory approval.

via Novartis|

#autoimmune #healthcare #ianalumab